Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS or COVID‐19: initial assessment

Review of 2 RCTs and 21 observational studies concludes available evidence shows it is uncertain whether lopinavir/ritonavir improves clinical outcomes in severe symptomatic disease or prevents infection among patients at high risk of acquiring COVID‐19.

Journal of the International AIDS Society